ArticleKidney international reports2023
Impact of Sodium-Glucose Cotransporter-2 Inhibitors on Urolithiasis.
Article in Kidney international reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it.
- SGLT2 inhibitors and nephrolithiasis risk: a meta-analysis.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2025Pooled it
- Empagliflozin in nondiabetic individuals with calcium and uric acid kidney stones: a randomized phase 2 trial.Nature medicine · 2025Trial
- SGLT2 Inhibitors in Nephrolithiasis: Emerging Evidence and What Urologists Need to Know.Medical sciences (Basel, Switzerland) · 2026Review
- Sodium-Glucose Cotransporter 2 Inhibitors Prevent Nephrolithiasis in Patients with Diabetes: A TriNetX-Based Real-World Global Comparison.Kidney360 · 2026Article
- Exploration of the association of antidiabetic drugs with urolithiasis: A drug-targeted Mendelian randomization study.Asian journal of urology · 2026Article
- Kidney stones and SGLT2 inhibitors.Clinical and experimental nephrology · 2025Article
- Sodium glucose co-transporter 2 inhibitor prevents nephrolithiasis in non-diabetes by restoring impaired autophagic flux.EBioMedicine · 2025Article
- SGLT2 Inhibitors and Their Effect on Urolithiasis: Current Evidence and Future Directions.Journal of clinical medicine · 2024Review
- Thiazide prescriptions are not associated with lower urolithiasis: a Japanese epidemiologic study.International urology and nephrology · 2023Article
- In Reply to "Letter Regarding 'Impact of Sodium-Glucose Cotransporter-2 Inhibitors on Urolithiasis'".Kidney international reports · 2023Article
- Sodium/Glucose Cotransporter 2 Inhibition and Urolithiasis: The Effect of Urinary pH and Citrate.Kidney international reports · 2023Article
- Sodium-glucose cotranspor ter 2 (SGLT2) inhibitors in nephrolithiasis: should we "gliflozin" patients with kidney stone disease?Jornal brasileiro de nefrologiaReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.